e-therapeutics plc – LSE:ETX.L
e-therapeutics stock price today
e-therapeutics stock price monthly change
e-therapeutics stock price quarterly change
e-therapeutics stock price yearly change
e-therapeutics key metrics
Market Cap | 56.38M |
Enterprise value | 3.85B |
P/E | -7.21 |
EV/Sales | 8458.15 |
EV/EBITDA | -1389.38 |
Price/Sales | 85.04 |
Price/Book | 1.59 |
PEG ratio | 0.07 |
EPS | -0.03 |
Revenue | N/A |
EBITDA | -19.50M |
Income | -16.50M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -514.69% |
Oper. margin | -633.33% |
Gross margin | 100% |
EBIT margin | -633.33% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freee-therapeutics stock price history
e-therapeutics stock forecast
e-therapeutics financial statements
| Oct 2021 | 0 | -2.63M | |
|---|---|---|---|
| Jul 2022 | 295K | -3.81M | -1292.2% |
| Jan 2023 | 180K | -4.46M | -2478.89% |
| Jul 2023 | 160K | -5.59M | -3496.25% |
| Apr 2022 | 25547000 | 1.09M | 4.28% |
|---|---|---|---|
| Jul 2022 | 25547000 | 1.18M | 4.63% |
| Oct 2022 | 34640000 | 1.59M | 4.61% |
| Jul 2023 | 28807000 | 1.27M | 4.43% |
| Jul 2021 | -3.03M | -45K | 21.65M |
|---|---|---|---|
| Jul 2022 | -4.71M | 14.91M | 8K |
| Jan 2023 | -2.83M | -76K | 13.03M |
| Jul 2023 | -6.54M | -108K | -188K |
e-therapeutics alternative data
| Aug 2023 | 38 |
|---|---|
| Sep 2023 | 38 |
| Oct 2023 | 38 |
| Nov 2023 | 38 |
| Dec 2023 | 34 |
| Jan 2024 | 34 |
| Feb 2024 | 34 |
| Mar 2024 | 34 |
| Apr 2024 | 34 |
| May 2024 | 34 |
| Jun 2024 | 34 |
| Jul 2024 | 34 |
e-therapeutics other data
| Patent |
|---|
Application Filling date: 31 May 2019 Issue date: 5 Aug 2021 |
Grant Filling date: 25 Oct 2017 Issue date: 30 Mar 2021 |
Application Filling date: 25 Oct 2017 Issue date: 20 Feb 2020 |
Grant Filling date: 2 Dec 2016 Issue date: 22 Oct 2019 |
| Insider | Compensation |
|---|---|
Mr. Ahmad Ali Mortazavi (1971) Chief Executive Officer & Director | $135,890 |
Mr. Michael Anthony Bretherton ACA, B.A. (1955) Interim Chief Financial Officer & Director | $39,000 |
-
What's the price of e-therapeutics stock today?
One share of e-therapeutics stock can currently be purchased for approximately $44.3.
-
When is e-therapeutics's next earnings date?
Unfortunately, e-therapeutics's (ETX.L) next earnings date is currently unknown.
-
Does e-therapeutics pay dividends?
No, e-therapeutics does not pay dividends.
-
How much money does e-therapeutics make?
e-therapeutics has a market capitalization of 56.38M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 50.47% to 477K US dollars.
-
What is e-therapeutics's stock symbol?
e-therapeutics plc is traded on the LSE under the ticker symbol "ETX.L".
-
What is e-therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of e-therapeutics?
Shares of e-therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are e-therapeutics's key executives?
e-therapeutics's management team includes the following people:
- Mr. Ahmad Ali Mortazavi Chief Executive Officer & Director(age: 54, pay: $135,890)
- Mr. Michael Anthony Bretherton ACA, B.A. Interim Chief Financial Officer & Director(age: 70, pay: $39,000)
-
How many employees does e-therapeutics have?
As Jul 2024, e-therapeutics employs 34 workers.
-
When e-therapeutics went public?
e-therapeutics plc is publicly traded company for more then 17 years since IPO on 28 Nov 2007.
-
What is e-therapeutics's official website?
The official website for e-therapeutics is etherapeutics.co.uk.
-
How can i contact e-therapeutics?
e-therapeutics can be reached via phone at +44 20 4551 8888.
e-therapeutics company profile:
e-therapeutics plc
etherapeutics.co.ukLSE
34
Biotechnology
Healthcare
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.
London, W2 6BD
:
ISIN: GB00B2823H99
CUSIP: G2899C106
